How to Monitor AUDIT Scores During Semaglutide Weight Loss Treatment
How should clinicians track alcohol use disorder symptoms in patients receiving semaglutide for weight loss?
Patients seeking obesity medicine or bariatric care may also have hazardous drinking or alcohol use disorder, and postoperative bariatric populations are at increased risk of developing alcohol use disorder. This case series describes a practical monitoring approach using repeated Alcohol Use Disorders Identification Test screening in patients who later received semaglutide for weight loss and showed marked reductions in alcohol-related symptoms.
-
Administer the AUDIT at intake
Use the Alcohol Use Disorders Identification Test at the initial obesity medicine or bariatric evaluation. In the clinic described in the article, the AUDIT was given to all new patients and captures self-reported frequency and quantity of alcohol use as well as mental state and experiences during use.
-
Interpret the baseline AUDIT score
Treat an AUDIT score above 8 as positive. Scores of 8 to 14 indicate hazardous alcohol consumption, while scores of 15 or higher indicate moderate to severe alcohol use disorder.
-
Identify patients with positive screening who start semaglutide
Flag patients who both screen positive on the AUDIT and are later prescribed semaglutide for weight loss. In this case series, those were the patients selected for retrospective follow-up of alcohol-related symptom change.
-
Repeat the AUDIT at follow-up visits
Re-administer the AUDIT at follow-up visits after semaglutide initiation. Follow-up timing in the series varied by individualized treatment plan, with reassessment occurring from 1 month to 9 months after baseline.
-
Compare baseline and follow-up scores
Track absolute change in AUDIT score over time rather than assuming alcohol improvement parallels weight loss. In this series, the mean AUDIT score fell from 14.0 to 4.5, and all 6 patients reached scores consistent with low-risk drinking at follow-up.
-
Interpret improvement cautiously in context
Consider other factors that may affect AUDIT change, including concomitant treatment and the possibility that repeated screening itself may alter drinking behavior. One patient was also prescribed topiramate, which is sometimes used off-label for alcohol use disorder, and the article notes that completing the AUDIT may itself have influenced alcohol use.
-
Continue standard evidence-based AUD care
Do not treat this case series as a validated protocol for semaglutide as alcohol use disorder therapy. The authors state that until randomized, placebo-controlled trial data are available, clinicians should direct patients toward psychological and pharmacologic interventions for alcohol use disorder that have already been validated.
Clinical Considerations
- This was a small retrospective case series of 6 patients from a single interdisciplinary obesity medicine and bariatric surgery clinic.
- Follow-up intervals were variable, only 2 time points were measured, and the study cannot determine whether AUDIT improvement persists long term.
- One patient also received topiramate, so the largest individual AUDIT reduction cannot be attributed solely to semaglutide.
- The article reports an association between semaglutide therapy for weight loss and lower AUDIT scores, not proof that semaglutide is an established treatment for alcohol use disorder.
Bottom Line
In patients receiving semaglutide for weight loss, repeated AUDIT screening can detect meaningful changes in alcohol-related symptoms, but semaglutide should not replace validated alcohol use disorder treatments based on this case series alone.
